These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19204165)

  • 1. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
    Stüve O; Leussink VI; Fröhlich R; Hemmer B; Hartung HP; Menge T; Kieseier BC
    Arch Neurol; 2009 Feb; 66(2):259-61. PubMed ID: 19204165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
    Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
    Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
    Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
    Bar-Or A; Calabresi PA; Arnold D; Markowitz C; Shafer S; Kasper LH; Waubant E; Gazda S; Fox RJ; Panzara M; Sarkar N; Agarwal S; Smith CH
    Ann Neurol; 2008 Mar; 63(3):395-400. PubMed ID: 18383069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.
    Cross AH; Stark JL; Lauber J; Ramsbottom MJ; Lyons JA
    J Neuroimmunol; 2006 Nov; 180(1-2):63-70. PubMed ID: 16904756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of neuromyelitis optica IgG antibody in an active relapsing-remitting multiple sclerosis population.
    Smith CH; Waubant E; Langer-Gould A
    J Neuroophthalmol; 2009 Jun; 29(2):104-6. PubMed ID: 19491632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD
    J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis.
    Petereit HF; Rubbert A
    Arch Neurol; 2005 Oct; 62(10):1641-2; author reply 1642. PubMed ID: 16216954
    [No Abstract]   [Full Text] [Related]  

  • 11. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial.
    Panitch H; Goodin D; Francis G; Chang P; Coyle P; O'Connor P; Li D; Weinshenker B;
    J Neurol Sci; 2005 Dec; 239(1):67-74. PubMed ID: 16169561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Vollmer TL; Wynn DR; Alam MS; Valdes J
    Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis.
    Petereit HF; Moeller-Hartmann W; Reske D; Rubbert A
    Acta Neurol Scand; 2008 Jun; 117(6):399-403. PubMed ID: 18031564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
    Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
    N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M;
    Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
    Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
    Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis.
    Cavaletti G; Perseghin P; Dassi M; Cavarretta R; Frigo M; Caputo D; Stanzani L; Tagliabue E; Zoia C; Grimaldi M; Isella V; Rota S; Ferrarese C; Frattola L
    Neurol Sci; 2006 Apr; 27(1):24-32. PubMed ID: 16688596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.